A microscopy study revealed tau controls Fyn clustering in dendrites. The findings shed new light on how certain forms of dementia may occur. Read More
A link between liver dysfunction and Alzheimer's disease has been discovered. The findings add to the understanding of the role metabolic dysfunction plays in the neurodegenerative disease. Read More
The risk of developing Alzheimer's disease is increased, and progression more rapid in women due to larger brain-wide accumulation and acceleration in the spread of tau. Read More
VPS35 is a novel critical component of tau metabolism and the pathology of neurodegenerative diseases. Read More
Using a gene vector, researchers channeled the blueprint of the human tau protein into different aged mice. After a period of twelve weeks, the tau protein spread twice as fast in older mice than the younger cohort. Findings shed light on why Alzheimer's is predominantly an age-related neurodegenerative disease. Read More
Sleep disruptions during middle age may be a potential biomarker for developing Alzheimer's disease later in life. Researchers found those who experienced sleep problems in their 40s and 50s had more amyloid beta accumulation in their brains later in life. Those whose sleep problems started in their 50s and 60s had increased levels of tau. Additionally, higher levels of tau were discovered in the brains of those who lacked synchronized brain waves associated with a good night's sleep. Read More
Study in mice and humans reveals reinforcing the activity of microglia could slow, or potentially halt, the proliferation of Tau tangles in Alzheimer's disease. Read More
Women with the ApoE e4 genetic risk factor for Alzheimer's are more susceptible to tau accumulation in the brain than men. Read More
Your sleep history during middle age may predict Alzheimer's pathology later in life. A decrease in sleep quality between 50 and 70 years of age is associated with higher levels of tau and amyloid beta in the brain. Changes in brain activity and quality of sleep could be a biomarker for Alzheimer's disease. Read More
During early Alzheimer's disease, SOD1 initially weakens levels of Tau protein. However, as the disease progresses, the antioxidant becomes less effective at protecting the brain against neurodegeneration. Read More
Researchers have engineered a vaccine using virus-like particles that target Tau tangles in mouse models of Alzheimer's disease. Following the administration of the vaccine, the mice developed antibodies that cleared tau proteins, with the response lasting for a month. The mice also showed improvements in memory based tests and had less brain shrinkage than their peers who did not receive the vaccine. This suggests the vaccine prevented apoptosis. Researchers hope to move the vaccine to human clinical trials in the future. Read More
Researchers have identified average levels of biological and anatomical brain changes associated with Alzheimer's disease over thirty years before symptoms appear. In those with genetic risk factors for Alzheimer's, researchers found changes in cognitive performance up to 15 years before becoming symptomatic. Changes in Tau levels in the cerebral spinal fluid appeared up to 34 years before dementia symptoms occurred, and physical changes to the medial temporal lobe were apparent up to 9 years before cognitive impairment was apparent. Read More
